Beefing up hepatitis efforts, GSK to acquire California firm for $57M

GlaxoSmithKline (NYSE: GSK) will acquire California-based Genelabs Technologies in a deal worth $57 million.

The Associated Press reports

According to a , GSK will incorporate Genelabs into its drug-discovery organization.

GSK employs several thousand people across the Research Triangle Park, N.C., region and operates one of its two U.S. headquarters in RTP.